International Stem Cell Corp. (ISCO) Moves toward Commencement of Phase I Clinical Trial through Partnership with Cryoport
Earlier this week, Cryoport, Inc. (NASDAQ: CYRX), the world’s premier cryogenic logistics firm, announced a strategic partnership with International Stem Cell Corp. (OTCQB: ISCO) through which it will provide global logistics support for ISCO’s impending Phase I clinical trial of its human parthenogenetic stem cell-derived neural stem cells (ISC-hpNSC) for the treatment of moderate to severe Parkinson’s disease. Cryoport’s strategically located cryogenic facilities in Southern California and Singapore are expected to play a key role in ISCO’s efforts to maintain its cell therapy as it is transported around the globe to the study’s site, Australia’s Florey Institute of Neuroscience and…